Poniard Pharmaceuticals Announces Promising Data From Interim
Safety Analysis of Phase 1 Combination Trials of Picoplatin in
Colorectal and Prostate Cancers
- Company Planning to Initiate Phase 2 Trials in Colorectal Cancerand in Hormone-Refractory Prostate Cancer in Q307 - SOUTH SAN FRANCISCO, Calif., June 01, 2007/PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , abiopharmaceutical company focused on oncology, today announcedpromising results from an interim safety analysis of two Phase 1dose-escalating trials of
picoplatin, a new ge...
Poniard Pharmaceuticals Announces Clinical Data from Picoplatin
Phase 2 Small Cell Lung Cancer Trial To Be Presented at American
Society of Clinical Oncology Annual Meeting
-- Data from
Picoplatin Phase 1 Colorectal and Prostate CancerTrials To Be Published in 2007 ASCO Proceedings -- SOUTH SAN FRANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCall/-- Poniard Pharmaceuticals, Inc. , a biopharmaceutical companyfocused on oncology, today announced that data from a Phase 2 trialof
picoplatin, the Company's lead product candidate, in patientswith small cell lung...